Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1-infected patients with no previous AIDS event (excluding a healed tuberculosis);~* Current antiretroviral treatment associating dolutegravir + abacavir + lamivudine for at least 1 month;~* Nadir CD4 ≥ 100/mm3;~* Plasma RNA viral load \< 50 copies/ml for at least 12 months;~* Plasma RNA viral load \<20 or 40 copies/ml (according to the threshold of the method used by local laboratory) at the screening visit;~* No documented virologic failure or known resistance to any integrase inhibitor,~* Patient having provided a written consent;~* Patients follow-up possible in ambulatory;~* Patient age \> 18 years;~* Covered by health insurance~Exclusion Criteria:~* Non-compliant patient~  * Subject is pregnant, or lactating, or of childbearing potential and without contraception;~ * Active opportunistic infections (defining AIDS);~ * Known hypersensibility to abacavir or lamivudine or dolutegravir;~ * Patients harboring HLA B\*5701;~ * Major overweight (BMI ≥ 40);~ * Weight \<40 kg;~ * Creatinine clearance \< 50ml/min;~ * Cirrhosis or severe liver failure (factor V \< 50%);~ * Life Prognosis threatened within 6 months;~ * Circumstances that may impair judgment or understanding of the information given to the patient;~ * Co-medication with carbamazepin, oxcarbamazepin, fosphenytoïn, phenobarbital, phenytoïn, primidon, St John's wort or dofetilid;~ * Malabsorption syndromes;~ * The following laboratory criteria:~    * Serum AST,ALT \> 5 x upper limit of normal (ULN)~   * Thrombocytopenia with platelet count \< 50.000/ml~   * Anemia with hemoglobin \< 8g/dl~   * Polynuclear neutrophil count \< 500/mm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- triple therapy (Type: ACTIVE_COMPARATOR): dolutegravir + abacavir + lamivudine (TRIUMEQ) : oral administration, one tablet daily during 48 weeks.
- monotherapy (Type: EXPERIMENTAL): dolutegravir (TIVICAY) : 50 mg, oral administration, one tablet daily during 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).